Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world

Berotralstat was associated with significant and sustained reductions in attack rates among patients with HAE, regardless of baseline attack rate. Patients with 0 baseline attacks/month maintained low attack rates following berotralstat initiation.